Early diagnosis can prevent CRE infections

What are CRE infections?

Due to carbapenem antibiotic resistance, gut bacteria, including E. coli and Klebsiella pneumoniae, generate Carbapenem-Resistant Enterobacterales (CRE), which are difficult to treat. Hospitalized patients with impaired immune systems or medical devices are especially at risk for life-threatening pneumonia, bloodstream, and urinary tract infections.

How CRE Spreads

• Hands, wounds, or stool can spread the disease.
• CRE can be transmitted by ventilators, catheters, and IV lines.
• Colonization: Symptomless carriers propagate CRE.
• Hospitals and nursing homes are hotspots.

Who Risks?

• Ventilator, catheter, and IV line patients.
• Long-term antibiotic users.
• Patients with impaired immune systems (cancer, HIV, and transplant).
• CRE infections mostly affect people with weakened immune systems.

Key Information: Rare but serious CRE infections mostly impact hospitalized patients. Most antibiotics are ineffective against them; thus, hand hygiene, antibiotic use, and hospital infection control are the best defenses.

ECR symptoms

The symptoms of Carbapenem-Resistant Enterobacteriaceae (CRE) infections vary by body part. Fever, chills, shortness of breath, cough, stomach pain, difficult urination, and surgery or wound redness or swelling are common symptoms. Because they defy most medications, these infections are dangerous and typically occur in hospitalized patients.

Typical Infection Site Symptoms

• Bloodstream (Sepsis): Fever, chills, weariness, weakness, disorientation, low blood pressure
• Urinary Tract (UTI): Urinating painfully, frequently, abdominal or pelvic pain
• Pneumonia: Cough, breathlessness, chest discomfort, fever
• Wounded/surgical sites: Redness, swelling, pus, itching, discomfort
• Abdomen: Tenderness, severe belly ache
• Rare meningitis: Stiff neck, headache, impaired awareness, seizures

Possible Risks

• Stay in the hospital or ICU with ventilators, catheters, or IV lines.
• Chronic antibiotic use promotes resistance.
• HIV, cancer, diabetes, and transplant patients have weakened immune systems.
• Children of all ages are more likely to experience serious consequences.

Complications

• Sepsis: Organ failure and death.
• High fatality rates: ~13% for UTIs, up to 50% for bloodstream infections.
• Treatment difficulty: Few antibiotics, needing complex combinations.

Seek Medical Help 

• Chronic fever or chills despite antibiotics.
• Severe wound or surgical pain or swelling.
• Unexpected confusion, convulsions, or blood pressure decline.
• Fever over 103°F (40°C) requires emergency care.

CRE causes and risks

Gut bacteria like E. coli and Klebsiella pneumoniae that are carbapenem-resistant cause CRE infections. Antibiotic usage, hospital exposure, and genetic transfer of resistance are the main causes, whereas prolonged hospitalization, invasive medical equipment, decreased immunity, and past antibiotic use are risk factors.

CRE Infection Causes

• Development of Antibiotic Resistance
• Chronic carbapenem and broad-spectrum antibiotic treatment helps bacteria to adapt and thrive.
• KPC, NDM, and OXA-48 carbapenemase enzymes from CRE bacteria break down carbapenem medicines.
• Horizontal gene transfer can spread resistance genes amongst bacteria, making outbreaks harder to suppress.

A Hospital Environment

• Frequent antibiotic use in ICUs and wards increases resistance.
• CRE can enter through contaminated catheters, ventilators, and IV lines.
• CRE can live on sinks, toilets, and medical equipment.

CRE infection risk factors

• Long hospital stays promote resistant bacteria exposure.
• Invasive equipment (catheters, ventilators, feeding tubes): Allow CRE entrance.
• Past CRE colonization/infection strongly predicts future CRE infection.
• Broad-spectrum antibiotics kill gut flora, promoting CRE.
• Chronic diseases (renal failure, diabetes, cancer, HIV): Weak immunity worsens infections.
• Immunosuppression makes organ/stem cell transplant patients vulnerable.
• Seniors and dependents are more likely to be exposed to polluted surfaces and feces.

Diagnostics of CRE

1. Sample Gathering

• Possible sepsis blood cultures.
• UTI urine samples.
• Stool or rectal swabs for colonization (some people have CRE without symptoms).
• Wound fluid/tissue samples for surgical site infections.

2. Lab Tests

• Culture and Sensitivity Testing
• Lab-grown bacteria are subjected to carbapenems.
• CRE strains grow despite carbapenem exposure.
• Antimicrobial susceptibility testing
• See which antibiotics still kill germs.
• Helps doctors choose effective treatments.

3. Rapid and molecular diagnostics

• The PCR method
• Finds carbapenemase genes (KPC, NDM, OXA-48, VIM, IMP).
• Excellent speed and accuracy.
• Carba NP Test
• Biochemical test for bacterial carbapenemase activity.
• Advance labs use Whole Genome Sequencing (WGS).
• Offers genetic details on resistance mechanisms.

Why Early Diagnosis Matters

• Up to 50% mortality for bloodstream infections.
• Identifying colonized patients helps hospitals segregate and prevent outbreaks.
• Targeted treatment: Quick diagnosis enables medical professionals to select a small number of potentially effective antibiotics.

Treating Enterobacteriaceae resistant to carbapenems

The video is about new trend in treating drug-resistant infections

CRE infections are difficult to treat because they resist most antibiotics, including carbapenems. For NDM, VIM, and IMP producers, doctors recommend contemporary combination treatments like ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and aztreonam. Lab susceptibility testing guides personalized treatment.

Current CRE Treatments

• New β-lactam/β-lactamase inhibitor formulations
• Ceftazidime-avibactam controls KPC-producing CRE.
• Meropenem-vaborbactam: For KPC-producing strains.
• Certain resistant Enterobacterales benefit from imipenem-relebactam.
• Regarding producers of metallo-β-lactamases (NDM, VIM, IMP),
• To overcome resistance, take Ceftazidime-avibactam and Aztreonam.

Other agents (susceptibility)

• Urinary tract infections may use aminoglycosides (amikacin, gentamicin, tobramycin).
• Polymyxins (Colistin, Polymyxin B)—last-resort medications with renal damage.
• Tigecycline treats intra-abdominal but not bloodstream infections.
• UTI treatment with fosfomycin.

The Treatment Challenges

• Bloodstream diseases can kill 50%.
• Polymyxins with tigecycline can be toxic.
• Few oral options: Most effective medications are IV.
• Resistance spread: NDM-producing CRE, initially found in India, are difficult to treat and spreading internationally.

Prevention

• Handwashing in healthcare is common.
• Avoid overusing antibiotics.
• Sterilization: Cleaning hospital equipment and surfaces.
• Hospital CRE screening and isolation practices.
• Avoid unnecessary carbapenem usage.
• Infection control: Patient screening, carrier isolation, and healthcare equipment disinfection.
• Sepsis management, ICU organ support, and monitoring.

Can CRE infections kill?

Carbapenem-Resistant Enterobacteriaceae (CRE) infections can kill vulnerable people. These bacteria resist almost all antibiotics, including carbapenems (the “last-resort” medications), making treatment challenging.

How CRE Can Kill

• High death rates:
• UTIs caused by CRE have a 13% fatality rate.
• Even with treatment, bloodstream infections can kill 40–50%.
• Septic shock and organ failure can result from CRE bloodstream dissemination.
• Only a few antibiotic combinations (such ceftazidime-avibactam + aztreonam) work, and resistance spreads.
• Hospital outbreaks: Ventilators, catheters, and immunocompromised ICU patients are particularly at danger.

Prevention is key

• Strict hospital infection control measures include patient segregation, hand washing, and sterilizing equipment.
• Carbapenem and broad-spectrum antibiotic stewardship: Avoiding needless use.
• Rectal swabs or PCR tests enable early detection and prevention.

The Treatment Challenges

• CRE resist most drugs, including carbapenems.
• Doctors may combine medications like:
• Colistin polymyxins
• Tigecycline
• Fosfomycin
• Gentamicin, tobramycin, aminoglycosides
• Lab testing determines drug efficacy and case-specific treatment.
• UTIs can kill 13% and bloodstream infections 50%.

Conclusion

One of the major worldwide health risks is Carbapenem-Resistant Enterobacteriaceae (CRE). These infections are caused by common gut bacteria that are resistant to carbapenem, such as E. coli and Klebsiella pneumoniae.

Hospitalized or immunocompromised patients can die from CRE infections, which are rare in healthy people. Our best strategies for combating this issue include prevention, timely diagnosis, and careful antibiotic usage, given the limited treatment options and the spread of resistance.